Home
About
Overview
Sharing Data
ORCID
Help
History (9)
The vulnerable preschool child: the impact of biomedical and social risks on neurodevelopmental function.
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
Near-infrared spectroscopy in neonates before palliation of hypoplastic left heart syndrome.
Articular fractures: does an anatomic reduction really change the result?
Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies.
See All 9 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies.
Acceptable recipient outcomes with the use of hearts from donors with hepatitis-B core antibodies. J Heart Lung Transplant. 2005 Jan; 24(1):34-7.
View in:
PubMed
subject areas
Adult
Aged
Female
Heart Transplantation
Hepatitis B Antibodies
Hepatitis B Core Antigens
Hepatitis B, Chronic
Humans
Lamivudine
Male
Middle Aged
New York
Postoperative Complications
Retrospective Studies
Reverse Transcriptase Inhibitors
Survival Analysis
Treatment Outcome
authors with profiles
Sean Pinney